Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astria Therapeutics Inc

5.99
+0.770014.75%
Post-market: 5.70-0.2900-4.84%17:06 EDT
Volume:664.91K
Turnover:3.89M
Market Cap:338.04M
PE:-3.19
High:6.09
Open:5.29
Low:5.28
Close:5.22
Loading ...

BRIEF-Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
04 Jun

Astria Therapeutics Announces New Stock Option Grants as Part of 2022 Inducement Stock Incentive Plan

Reuters
·
04 Jun

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Jun

Astria Therapeutics CEO to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Reuters
·
28 May

Astria Therapeutics Inc. to Present at C1 Inhibitor Deficiency and Angioedema Workshop in Budapest

Reuters
·
23 May

Astria Therapeutics to Present at Eastern Allergy Conference on Hereditary Angioedema Trial Results

Reuters
·
22 May

Astria Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Astria Therapeutics Price Target Maintained With a $47.00/Share by Cantor Fitzgerald

Dow Jones
·
14 May

Astria Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview

Reuters
·
14 May

Astria Therapeutics Shares Rise Following Update on In-Development Drugs

Dow Jones
·
14 May

BRIEF-Astria Therapeutics Q1 Operating Expenses USD 36.995 Million

Reuters
·
14 May

Astria Therapeutics Reports Q1 2025 Financial Results: Net Cash Used in Operations Increases to $34 Million

Reuters
·
14 May

Astria Therapeutics Q1 Operating Expenses USD 36.995 Million

THOMSON REUTERS
·
14 May

Press Release: Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
14 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 May

Astria Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
05 May

Astria Therapeutics Announces New Stock Option Grants Under 2022 Inducement Plan for New Employees

Reuters
·
03 May

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 May

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Business Wire
·
01 May

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Business Wire
·
30 Apr